These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 31845896)
1. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study. Brugaletta S; Gori T; Tousek P; Gomez-Lara J; Pinar E; Ortega-Paz L; Schulz E; Kocka V; Münzel T; Cequier À; Buono A; Serruys PW; Sabaté M; EuroIntervention; 2020 Mar; 15(16):1436-1443. PubMed ID: 31845896 [TBL] [Abstract][Full Text] [Related]
2. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]
3. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. Cassese S; Katagiri Y; Byrne RA; Brugaletta S; Alfonso F; Räber L; Maeng M; Iñiguez A; Kretov E; Onuma Y; Joner M; Sabaté M; Laugwitz KL; Windecker S; Kastrati A; Serruys PW EuroIntervention; 2020 Mar; 15(16):1451-1457. PubMed ID: 30719976 [TBL] [Abstract][Full Text] [Related]
4. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries. Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648 [TBL] [Abstract][Full Text] [Related]
5. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy. Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079 [TBL] [Abstract][Full Text] [Related]
6. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419 [TBL] [Abstract][Full Text] [Related]
7. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW; JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240 [TBL] [Abstract][Full Text] [Related]
8. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423 [TBL] [Abstract][Full Text] [Related]
9. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study). Moscarella E; Tanaka A; Ielasi A; Cortese B; Coscarelli S; De Angelis MC; Piraino D; Latib A; Grigis G; Bianchi R; Buccheri D; Calabrò P; Tespili M; Silva Orrego P; Colombo A; Varricchio A Catheter Cardiovasc Interv; 2018 Oct; 92(4):668-677. PubMed ID: 29356269 [TBL] [Abstract][Full Text] [Related]
10. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590 [TBL] [Abstract][Full Text] [Related]
11. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. Cassese S; Byrne RA; Jüni P; Wykrzykowska JJ; Puricel S; Ndrepepa G; Schunkert H; Fusaro M; Cook S; Kimura T; Henriques JPS; Serruys PW; Windecker S; Kastrati A EuroIntervention; 2018 Jan; 13(13):1565-1573. PubMed ID: 28671552 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials. Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954 [TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial. Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029 [TBL] [Abstract][Full Text] [Related]
14. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ; JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial. Gomez-Lara J; Brugaletta S; Ortega-Paz L; Vandeloo B; Moscarella E; Salas M; Romaguera R; Roura G; Ferreiro JL; Teruel L; Gracida M; Windecker S; Serruys PW; Gomez-Hospital JA; Sabaté M; Cequier A JACC Cardiovasc Interv; 2018 Aug; 11(16):1559-1571. PubMed ID: 29805111 [TBL] [Abstract][Full Text] [Related]
16. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232 [TBL] [Abstract][Full Text] [Related]
17. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials. Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495 [TBL] [Abstract][Full Text] [Related]
18. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. Arroyo D; Togni M; Puricel S; Gerard B; Sonja L; Corpataux N; Villeneuve H; Boute E; Stauffer JC; Goy JJ; Cook S Trials; 2014 Jan; 15():9. PubMed ID: 24398143 [TBL] [Abstract][Full Text] [Related]
19. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent). Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236 [TBL] [Abstract][Full Text] [Related]
20. Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies. Tarantini G; Masiero G; Barioli A; Paradies V; Vlachojannis G; Tellaroli P; Cortese B; di Palma G; Varricchio A; Ielasi A; Loi B; Steffenino G; Ueshima D; Mojoli M; Smits P Catheter Cardiovasc Interv; 2018 Aug; 92(2):E115-E124. PubMed ID: 29513403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]